TSTatiana V. Strokova

Tatiana V. Strokova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tatiana V. Strokova has a total of 306 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recurrent Acute Liver Failure as the First Manifestation of ARCN1-Associated Disorder Caused by a Terminal Exon Frameshift Variant

    by Varvara Shleptsova, Ekaterina Nuzhnaya, Natalia Taran, Evgeny Tatarsky, Alexandra Nikolaeva, Philipp Sviridov, Tatiana Strokova, Natalia Semenova

    Background: ARCN1-related syndrome (short stature-micrognathia syndrome, SSMG; OMIM #617164) is an autosomal dominant disorder caused by loss-of-function variants in the ARCN1 gene, which encodes the δ-COP (COPD) subunit of the COPI coatomer complex. The condition is classically characterized by intrauterine growth restriction (IUGR), short stature with rhizomelic shortening, microcephaly, micrognathia, facial dysmorphism, and global developmental delay. Methods: Clinical examination, blood tests and genetic analysis were performed. Whole-exome sequencing and Sanger analysis were conducted, followed by bioinformatics analysis and ACMG-based variant interpretation to identify and characterize the pathogenic variant. Results: We report a male proband with a previously undescribed variant in the ARCN1 gene, presenting with an atypical phenotype. Notably, the patient lacked the classical syndromic features, including short stature, microcephaly, IUGR, and developmental delay. The predominant clinical manifestation was transient hepatic dysfunction occurring during febrile episodes, which resolved between acute events. On physical examination, rhizomelic shortening and dysmorphic facial features, including mild micrognathia, were found. Overall, identified symptoms were mild in severity, which may be associated with the variant’s location within the gene. Conclusions: We describe a novel likely pathogenic variant in the ARCN1 gene associated with a mild phenotype of SSMG. This case expands the phenotypic spectrum of ARCN1-related syndrome and highlights the importance of considering this diagnosis in patients with unexplained recurrent liver injury, even in the absence of classical syndromic features.

  • Open Access

    Current Clinical Guidelines for the Management of Children Over One Year of Age with Malnutrition (Protein-Energy Malnutrition)

    by Anna A. Alekseeva, Aleksander A. Baranov, Tatyana T. Batysheva, Irina A. Belyaeva, Tatyana E. Borovik, Bushueva V. Tatyana, Olga V. Bykova, Olga B. Gordeeva, Valentina I. Guzeva, Sergey A. Gureev, et al.

    In May 2026, the Ministry of Health of the Russian Federation approved new clinical guidelines for the management of children over one year of age with protein-energy malnutrition. The document establishes unified rules for diagnosis, assessment of severity based on weight loss and body mass index, as well as standards for nutritional management and medical care. The guidelines provide a legitimate legal basis for prescribing specialized enteral and parenteral nutrition within the framework of compulsory health insurance, which significantly expands access to nutritional support. The document was developed by members of the Union of Pediatricians of Russia, the Association of Professional Participants in Hospice Care, the Russian Gastroenterological Association, the Autonomous Non-Profit Organization “Society of Pediatric Gastroenterologists, Hepatologists and Nutritionists”, the National Association of Pediatric Rehabilitologists, the Interregional Public Organization “Scientific Community for Promoting the Clinical Study of the Human Microbiome”, and the Russian Organization of Dietitians, Nutritionists and Food Industry Specialists.

  • Open Access

    Bioimpedance analysis parameters and metabolic profile in children with non-alcoholic fatty liver disease

    by A.м. Yakubovich, E.V. Pavlovskaya, M.E. Bagaeva, A.I. Zubovich, E.A. Kiselnikova, I.V. Vorozhko, T.V. Strokova

    Показатели биоимпедансного анализа и метаболический профиль у детей при неалкогольной жировой болезни печени

  • Diseases of the upper gastrointestinal tract in pregnancy: what should the gastroenterologist consider?

    by E.P. Yakovenko, T.V. Strokova, A.N. Ivanov, A.V. Yakovenko, Yu.V. Grigorieva

    Diseases of the upper gastrointestinal (GI) tract are among the most common extragenital pathologies in pregnant women. Hormonal and physiological changes occurring during pregnancy can trigger or exacerbate conditions such as gastroesophageal reflux disease (GERD), functional dyspepsia, chronic gastritis, and peptic ulcer disease. The rational selection of pharmacotherapy requires careful consideration of drug safety for both the mother and the fetus. Objective. To summarize current evidence-based data on the diagnosis, natural history, and treatment of the most common upper GI diseases in pregnant women. Key points. This review discusses major gastroenterological disorders in pregnant women, including their pathogenesis, clinical manifestations, and diagnostic methods. Approaches to treatment are outlined in accordance with international and national guidelines, with a particular focus on pharmacotherapy and the FDA drug safety classification system. Algorithms for patient management are presented, emphasizing risk minimization for the fetus while ensuring effective treatment for the mother. Conclusion. Early diagnosis and appropriate treatment of gastroenterological disorders in pregnant women can reduce complications and improve patient quality of life. The management of such cases requires a multidisciplinary approach involving both a gastroenterologist and an obstetrician.

  • Open Access

    Draft Clinical Guidelines for the Diagnosis and Treatment of Metabolically Associated Fatty Liver Disease in Children (Non-Alcoholic Fatty Liver Disease)

    by Alexander A. Baranov, Galina V. Volynets, Nikolay N. Vlasov, Larisa G. Goryacheva, Margarita M. Gurova, Vera A. Greshnyakova, Anna N. Zaviyalova, Nina V. Evdokimova, Marina Yu. Komissarova, Leyla S. Namazova-Baranova, et al.

    The authors present modern epidemiological data and features of the etiopathogenesis of metabolically associated fatty liver disease in children (non-alcoholic fatty liver disease), and provide clinical characteristics of various variants of this nosology. Information is provided on laboratory, instrumental and morphological signs of metabolically associated fatty liver disease in children, as well as on methods of prevention, treatment and rehabilitation in accordance with developed clinical guidelines.


  • Open Access

    Drug-associated nephrotic syndrome in a child with Wilson's disease

    by Svetlana S. Paunova, Natalia V. Labutina, Maria N. Zubavina, Madina M. Shibilova, Tamara A. Skvortsova, Tatyana V. Strokova, Madlena E. Bagaeva, Artyom V. Nikitin, Claudia K. Do Egito, Asiya I. Safina, et al.

    BACKGROUND: Wilson's disease (WD) (synonyms: Wilson–Konovalov disease, hepatolenticular degeneration, hepatocerebral dystrophy) is a rare, severe, hereditary multisystem disorder that manifests itself primarily in liver, neurological, and psychiatric disorders due to excessive copper deposition in organs and tissues. The long latent course and polymorphism of clinical symptoms make diagnostics difficult. WD manifests itself in childhood, adolescence, and later in life. WD diagnostics is based on a combination of clinical symptoms, laboratory test data (determination of ceruloplasmin levels in the blood, copper excretion in the urine), and molecular genetic testing. Complex treatment of WD primarily involves adherence to a copper-eliminating diet. A mandatory condition for the effectiveness of treatment of patients with WD is lifelong chelation therapy. The drug of choice in all age groups is penicillamine (a penicillin derivative), which has a significant number of side effects. Adverse reactions against the background of penicillamine therapy develop in about 30% of cases. These include changes in the nervous system (loss of taste, pyridoxine-deficiency polyneuritis), respiratory system (interstitial pneumonitis, diffuse fibrosing alveolitis, Goodpasture's syndrome), digestive system (decreased appetite, nausea, vomiting, diarrhea, aphthous stomatitis, glossitis, intrahepatic cholestasis, pancreatitis), kidneys (nephritis, nephrotic syndrome, hematuria). CLINICAL CASE DESCRIPTION: The case history of a 6-year-old girl with WD is analyzed. The peculiarity of the clinical case presented by us is the latent course of the disease, which was suspected when cytolysis syndrome was detected in connection with an examination for episodic abdominal pain. Further examination showed a decrease in the concentration of ceruloplasmin, initially borderline values of copper excretion in urine, and questionable values in the penicillamine test. Molecular genetic testing was important for establishing the diagnosis, and confirming the diagnosis. Prescribed chelation therapy with penicillamine led to the normalization of cytolysis syndrome parameters, but caused serious adverse events in the form of nephrotic syndrome, which required replacing penicillamine with trientine and prescribing glucocorticoids. Against the background of treatment correction, stable clinical and laboratory remission of nephrotic syndrome was achieved with satisfactory renal and liver function parameters and no manifestations of cytolysis. CONCLUSION: A moderate increase in biochemical markers of cytolysis, cholestasis, and bilirubin concentration, refractory to standard treatment, requires in-depth examination, including molecular genetics, to exclude WD. If side effects of penicillamine derivatives are detected, immediate correction of pathogenetic therapy with replacement of the chelating drug is necessary.

  • Association between breastfeeding duration and bone mineral density in adolescents with inherited metabolic diseases affecting the liver

    by K.YU. Rakhmanina, N.N. Taran, E.V. Pavlovskaya, I.F. Tin, M.E. Bagaeva, A.I. Zubovich, I.A. Matinyan, E.A. Kiselnikova, T.V. Strokova

    Objective. To study the association between bone mineral density (BMD) and breastfeeding duration (BFD) in adolescents with inherited metabolic diseases affecting the liver. Patients and methods. The study included 40 patients aged 14 to 19 years with inherited metabolic diseases (glycogen storage disease, Wilson’s disease and lysosomal acid lipase deficiency). BFD was assessed in months during which the child received breast milk without the introduction of infant formulas. BMD was measured in the lumbar spine using dual-energy X-ray absorptiometry. Results. A moderate positive correlation was found between BMD Z-score and BFD (rs = 0.326, p < 0.05), BMD Z-score and height Z-score (rs = 0.373, p < 0.05), and between BMD Z-score and BMI Z-score (rр = 0.387, p < 0.05). BMD Z-score was significantly higher in the group of adolescents with BFD ≥ 9 months than in the group with BFD ≤ 8 months (-0.379 ± 1.13 and -1.295 ± 1.48, p = 0.036). Conclusion. BMD values in adolescence with inherited metabolic diseases affecting the liver are higher with prolonged breastfeeding in infancy and early childhood. Key words: breastfeeding, adolescents, bone mineral density, inherited metabolic diseases

  • Current possibilities for diet optimization in children with obesity

    by E.V. Pavlovskaya, M.E. Bagaeva, N.N. Taran, T.V. Strokova, A.V. Starodubova

    The insufficient efficacy of obesity treatment in children and adolescents determines the need to develop new approaches to diet therapy as the main method of treating this disease in childhood. To date, the attention is paid to controlling the macronutrient composition and energy value of the diet, as well as the use of dietary types (models), primarily the Mediterranean diet. To optimize therapeutic nutrition, specialized food products are created that improve the efficacy of treatment and adherence to it. This article summarizes the results of recent studies on the possibility of including certain nutrients in the diet of obese children. The assessment of the impact of nutrients on body composition, anthropometric and metabolic parameters showed that vitamin D, L-citrulline, L-arginine and L-carnitine supplements have the most favorable efficacy and safety profile. Vitamin D helps to reduce cardiometabolic risk factors in obese children, but its effect on nutritional status continues to be discussed. The need for this vitamin in obese children is higher than in the general pediatric population. L-arginine and L-citrulline allow stabilizing and increasing muscle mass when following a low-calorie diet, as well as optimizing lipid and carbohydrate metabolism. The role of L-carnitine in obesity is determined by its antioxidant effects and elevated mitochondrial activity. Key words: obesity, children, vitamin D, L-citrulline, L-arginine, diet therapy, specialized food products

  • Experience with the use of adapted milk formula enriched with lactoferrin in infants during the first months of life

    by N.N. Taran, L.V. Ledyaikina, Z.M. Zainudinov, V.A. Revyakina, T.V. Strokova, O.N. Titova, O.A. Chirkova, I.V. Vorozhko, M.M. Chudova, T.N. Korotkova, et al.

    A topical and innovative area in the local food industry is the development of breast-milk substitutes enriched with lactoferrin. Objective. To study the clinical efficacy of adapted milk formula based on the carbohydrate and protein component (SDS-90) enriched with lactoferrin in children aged 0 to 6 months. Patients and methods. This open-label, single-center, prospective clinical study evaluated the clinical efficacy and tolerability of adapted milk formula based on the carbohydrate and protein component (SDS-90) enriched with lactoferrin in 20 children (median age 2.65 [1.5; 3.5] months). The criterion for efficacy was the dynamics of anthropometric parameters, and the criterion for tolerability was the dynamics of skin and gastrointestinal symptoms (regurgitation, flatulence, frequency and nature of stools). These symptoms were assessed at the beginning of the study and after 1 month. Results. During the observation period, the median increase in height was 2.5 [2.0; 3.0] cm and in body weight – 775 [650; 825] g, which indicates optimal rates of physical development. At the time of inclusion in the study, dry skin was recorded in 2 (10%) children, acne in 1 (5%) child, and after 1 month of receiving the formula, all children had clear skin. Functional regurgitation at the time of transfer to the study formula was diagnosed in 7 (35%) children (single volume – 10–20 mL), at the end of the study it persisted in only 2 (10%) children, with a frequency of 2–3 times per day (single volume – up to 10 mL). At baseline, flatulence was observed in 8 (40%) children, colic in 10 (50%), frequent stools (6–8 times per day) in 10 (50%), and constipation (no stools for >48 hours) in 4 (20%). After 1 month of receiving the formula, flatulence and colic were not observed in any of the children, and the frequency of stools decreased to 1–3 times per day in 12 (60%) children and to 4–6 times per day in 8 (40%) children. Conclusion. The results demonstrate the feasibility of enriching breast-milk substitutes with lactoferrin, a biologically active multifunctional glycoprotein isolated from cow’s colostrum. Key words: artificial feeding, cow’s milk protein, adapted milk formula, lactoferrin, secretory IgA, mucosal immunity, serum iron, ferritin, functional gastrointestinal disorders, gastrointestinal symptoms

  • Experience with trientine in children with Wilson's disease: a retrospective analysis of treatment efficacy

    by M.E. Bagaeva, T.V. Strokova, A.I. Zubovich, E.V. Pavlovskaya, E.A. Kiselnikova

    The pathogenetic method of treating Wilson's disease (WD) is the prescription of copper chelators. The first-line therapy drug is D-penicillamine; if it is ineffective or causes adverse effects, trientine is prescribed. Experience with trientine therapy in Russia is limited, and we therefore consider it necessary to present our experience with the use of this drug. Objective. To evaluate the efficacy of pathogenetic therapy with trientine in children with Wilson's disease. Patients and methods. A single-center observational retrospective study included data from patients with a verified diagnosis of BV receiving therapy with trientine. Treatment was considered effective when patients achieved transaminase (alanine aminotransferase, aspartate aminotransferase) values within 1 upper limit of normal and daily copper excretion in urine of 200 to 500 μg/day. Trientine was prescribed at a dosage of 20 mg/day. The data were obtained from the patients' primary medical records – the results of examinations conducted at the clinic once every 6 months. The data collected included anamnestic, clinical, laboratory (biochemical blood and urine tests, molecular genetic tests), instrumental, and ophthalmological examination data. Results. The study included 5 patients (2 boys and 3 girls) with Wilson's disease aged 6 to 17 years. Four of the five patients had hepatic Wilson's disease, and one had mixed Wilson's disease. The median age at diagnosis of Wilson's disease was 7.5 [6.5; 8.0] years; and the median age at the start of the study was 8.0 [8.0; 14.0] years. The median duration of therapy with trientine was 5 [3.0; 7.0] years. The median time to achieve the efficacy criterion was 1.5 [1.0; 2.0] years. According to the results of ultrasound elastography of the liver, all patients showed regression of fibrosis from F2 to F0 and steatosis from S1 to S0 after 12–24 months. No side effects (allergic rashes, dyspepsia, anemia, nephropathy) were recorded in any of the children. Conclusion. Pathogenetic therapy with trientine as a second-line drug in cases of intolerance to D-penicillamine and zinc preparations is effective, as confirmed by normalization of cytolysis syndrome, daily copper excretion in urine, reduction in the degree of fibrosis and steatosis of the liver, and absence of side effects. Key words: children, Wilson's disease, chronic hepatitis, trientine, treatment